Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
NCT ID: NCT00004999
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE2
350 participants
INTERVENTIONAL
1999-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lamivudine/Zidovudine
Capravirine
Nelfinavir mesylate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are HIV-positive.
* Are at least 18 years old.
* Have a CD4 cell count of more than 50 cells/mm3.
* Have an HIV level of more than 5000 copies/ml.
Exclusion Criteria
* Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
* Have taken an experimental drug within 28 days of study entry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agouron Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Clinical Research Ctr Inc
Tucson, Arizona, United States
Univ of Southern California
Los Angeles, California, United States
Highland Gen Hosp / San Francisco Gen Hosp
Oakland, California, United States
ViRx Inc
Palm Springs, California, United States
Research & Treatment at the California Pacific Med Ctr
San Francisco, California, United States
Harbor - UCLA Med Ctr
Torrance, California, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Bach and Godofsky
Bradenton, Florida, United States
Community Health Care
Fort Lauderdale, Florida, United States
Univ of Florida
Jacksonville, Florida, United States
Univ of Miami School of Medicine
Miami, Florida, United States
South Shore Hosp
Miami, Florida, United States
Specialty Med Care Ctrs of South Florida Inc
Miami, Florida, United States
Orange County Health Dept
Orlando, Florida, United States
Larry Bush
Palm Springs, Florida, United States
Infectious Diseases Associates
Sarasota, Florida, United States
Infectious Disease Research Institute
Tampa, Florida, United States
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, United States
Polk County Health Dept
Winter Haven, Florida, United States
Sky Blue
Boise, Idaho, United States
Northwestern Univ Med Ctr
Chicago, Illinois, United States
The CORE Ctr
Chicago, Illinois, United States
Indiana Univ Infectious Disease Research Clinic
Indianapolis, Indiana, United States
Univ of Iowa
Iowa City, Iowa, United States
Univ of Kansas School of Medicine
Wichita, Kansas, United States
University of Louisville / ID Division
Louisville, Kentucky, United States
HIV Outpatient Clinics / LA State Univ Med Ctr
New Orleans, Louisiana, United States
Fenway Community Health Ctr
Boston, Massachusetts, United States
Hawthorne Med Associates / PAACA
New Bedford, Massachusetts, United States
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States
Univ of Nebraska Medical Ctr
Omaha, Nebraska, United States
Paul Alessi
Cherry Hill, New Jersey, United States
VAMC New Jersey Healthcare System
East Orange, New Jersey, United States
St Mary's Hosp Family Treatment Ctr
Hoboken, New Jersey, United States
Univ of Med & Dentistry of New Jersey
Newark, New Jersey, United States
Bentley-Salick Medical Practice PC
New York, New York, United States
Univ of Rochester Med Ctr
Rochester, New York, United States
Univ of Cincinnati / Holmes Hosp
Cincinnati, Ohio, United States
Med Univ of South Carolina
Charleston, South Carolina, United States
Julio Arroyo
West Columbia, South Carolina, United States
Southwest Infectious Diseases Associates
Dallas, Texas, United States
Univ TX Galveston Med Branch
Galveston, Texas, United States
Joseph C Gathe
Houston, Texas, United States
Thomas Street Clinic
Houston, Texas, United States
Hampton Roads Med Specialists
Hampton, Virginia, United States
Wisconsin AIDS Research Consortium
Milwaukee, Wisconsin, United States
Canadian HIV Trials Network
Vancouver, British Columbia, Canada
QEII Health Science Centre
Halifax, Nova Scotia, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Immunity Care and Research Inc
Santo Domingo, , Dominican Republic
Univ of Puerto Rico School of Med
Rio Piedras, , Puerto Rico
Clinical Research Puerto Rico Inc
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AG1549-504
Identifier Type: -
Identifier Source: secondary_id
286C
Identifier Type: -
Identifier Source: org_study_id